- Home
- CBRE vs INAB Comparison
CBRE vs INAB Comparison
Compare CBRE & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CBRE | INAB |
|---|---|---|
| Founded | 1906 | 2016 |
| Country | United States | United States |
| Employees | 44000 | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.7B | 22.9M |
| IPO Year | 2001 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CBRE | INAB |
|---|---|---|
| Price | $133.64 | $1.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $177.86 | $6.00 |
| AVG Volume (30 Days) | ★ 2.0M | 35.9K |
| Earning Date | 04-23-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.61 | N/A |
| EPS | ★ 3.85 | N/A |
| Revenue | ★ $40,550,000,000.00 | N/A |
| Revenue This Year | $14.53 | N/A |
| Revenue Next Year | $9.05 | N/A |
| P/E Ratio | $34.61 | ★ N/A |
| Revenue Growth | ★ 13.37 | N/A |
| 52 Week Low | $108.45 | $0.12 |
| 52 Week High | $174.27 | $4.20 |
Technical Indicators
Market Signals| Indicator | CBRE | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 34.67 | 44.20 |
| Support Level | $127.40 | $1.52 |
| Resistance Level | $136.89 | $1.81 |
| Average True Range (ATR) | 3.72 | 0.17 |
| MACD | 0.25 | 0.02 |
| Stochastic Oscillator | 27.93 | 23.53 |
Price Performance
Historical ComparisonAbout CBRE CBRE Group Inc
CBRE Group provides a wide range of real estate services to owners, occupants, and investors worldwide, including leasing, property and project management, and capital markets advisory. CBRE's investment management arm manages over $140 billion for clients across diverse public and private real estate strategies.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.